Theodore Friedmann, A.B., M.D.
University of Pennsylvania and M.A., University of Oxford. Dr. Friedmann continues to study Lesch Nyhan Disease (LND), a neuro-developmental disease. His lab is concentrating on microarray and proteomic characterizations of human fibroblasts derived from LND patients, and of affected brain regions of the HPRT gene knockout mouse model. Dr. Friedmann’s lab has identified a number of genes and gene families that are aberrantly expressed in LND, and is presently examining their potential role in the development of the disorder’s neuropathology. The lab is using microarray and proteomic approaches to characterize the molecular basis for the defect in the basal ganglia dopamine pathways by beginning to characterize the molecular events that accompany the differentiation of human embryonic stem cells toward the dopaminergic neuronal phenotype. Dr. Friedmann is continuing to study the assembly and gene transfer properties of synthetic virus-like nanoparticles (virosomes), and the molecular mechanisms of growth enhancement by the growth factor IGF-1 in cultured cells and in mice in vivo. In addition, he has continued an extensive series of studies in vitro and in vivo of the mechanism of action of insulin-like growth factor (IGF-1), using gene expression and proteomic approaches. As part of that research program, he has established a bioinformatic facility under the sponsorship of the World Anti-Doping Agency (WADA) that will coordinate the worldwide research program of growth factors and related functions under the auspices of WADA.